Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 6/2021

01.06.2021 | Leukemia (A Aguayo, Section Editor)

Erythroleukemia: an Update

verfasst von: Olga K. Weinberg, Daniel A. Arber

Erschienen in: Current Oncology Reports | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset.

Recent Findings

The 2016 WHO classification includes more clear and restrictive diagnostic criteria for AEL. Primary acute erythroid leukemia is associated with complex and high-risk karyotypes including chromosomes 5q and 7q abnormalities. Mutational data shows that AEL is characterized by far lower NPM1 and FLT3-ITD mutation rates and higher mutational rates in TP53 compared with other AML subtypes. Hypomethylating agents have shown therapeutic value in AEL.

Summary

In this article, we discuss the evolving diagnostic concepts of erythroleukemia, genomics, clinical outcome, and promising therapeutic targets through an appraisal of the current literature.
Literatur
1.
Schwartz SO, Critchlow J. Erythremic myelosis (DI Guglielmo’s disease); critical review with report of four cases, and comments on erythroleukemia. Blood. 1952;7(8):765–93.CrossRef
2.
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.CrossRef
3.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukemias. Br J Haematol. 1976;33:451–8.CrossRef
4.
Villeval JL, Cramer P, Lemoine F, Henri A, Bettaieb A, Bernaudin F, et al. Phenotype of early erythroblastic leukemias. Blood. 1986;68(5):1167–74.CrossRef
5.
Kowal-Vern A, Cotelingam J, Schumacher HR. The prognostic significance of proerythroblasts in acute erythroleukemia. The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol. 1992;98(1):34–40.CrossRef
6.
Mazzella FM, Kowal-Vern A, Shrit MA, Wibowo AL, Rector JT, Cotelingam JT. et alR. Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis. Am J Clin Pathol. 1998;110(5):590–8.CrossRef
7.
Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:626–9.CrossRef
8.
Brunning RD, Matutes E, Flandrin G, Jaffe ES, Harris NL, Stein H, Vardiman JW. et al. Acute myeloid leukaemia not otherwise categorised., World Health Organization Classification of Tumours, 2001 Lyon, FranceI ARC Press(pg. 91-105)
9.
Arber DA, Brunning RD, Orazi A, Porwit A, Peterson L, Thiele J, et al. Acute myeloid leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classifiction of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 134–6.
10.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.CrossRef
11.
Santos FPS, Bueso-Ramos CE, Ravandi F. Acute erythroleukemia: diagnosis and management. Expert Rev Hematol. 2010;3(6):705–18.CrossRef
12.
Barnard DR, Alonzo TA, Gerbing RB, Lange R, Woods WG. Children’s Oncology Group Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatr Blood Cancer. 2007;49(1):17–22.CrossRef
13.
Hasserjian RB, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115(10):1985–92.CrossRef
14.
Olopade OI, Thangavelu M, Larson RA, Mick R, Kowal-Vern A, Schumacher HR, et al. Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood. 1992;80:2873–82.CrossRef
15.
Li H, Hasserjian RP, Kroft SH, Harrington AM, Wheaton SE, Pildain A, et al. Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms. Am J Clin Pathol. 2016;145(4):538–51.CrossRef
16.
Domingo-Claros A, Larriba I, Rozman M, Irriguible D, Vallespí T, Aventin A, et al. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematologica. 2002;87(2):148–53.PubMed
17.
• Reinig EF, Greipp PT, Chiu A, Howard MT, Reichard KK. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Mod Pathol. 2018;31:705–17 This series of pure erythroid leukemia illustrates high rate of very complex karyotype in this disease.CrossRef
18.
Sondergaard-Petersen H Erythrophagocytosis by pathological erythroblasts in the Di Guglielmo syndrome. A study of 18 cases. Scand J Haematol. 1974;13(4):260-5. (19). Histopathology 2017, 71, 316-321
19.
Hasserjian RP. Erythroleukemia and Its Differential Diagnosis. Surg Path Clin. 2013;6:641–59.CrossRef
20.
Greaves MF, Sieff C, Edwards PA. Monoclonal antiglycophorin as a probe for erythroleukemias. Blood. 1983;61(4):645–51.CrossRef
21.
Gupta AD, Dhond SR. Phenotypic heterogeneity of erythroblasts in erythroblastic leukemia revealed by monoclonal antibodies. Am J Hematol. 1988;29(1):12–7.CrossRef
22.
Garand R, Duchayne E, Blanchard D, Robillard N, Kuhlein E, Fenneteau O, et al. Minimally differentiated erythroleukaemia (AML M6 ‘variant’): a rare subset of AML distinct from AML M6. Groupe Français d'Hématologie Cellulaire. Br J Haematol. 1995;90(4):868–75.CrossRef
23.
• Lee WY, Weinberg OW, Pinkus GS. GATA1 Is a sensitive and specific Nuclear marker for erythroid and megakaryocytic lineages. Am J Clin Pathol. 2017;147(4):420–6 This study shows that blasts in acute erythroleukemia exhibit intense nuclear GATA1 positivity.CrossRef
24.
Wong E, Ling V, Westerman D, Morgan S, Juneja S. How unique is pure erythroid leukaemia? A retrospective analysis of seven cases and review of the literature. JCP. 2015;68:301–5.PubMed
25.
• Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, et al. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol. 2016;29:1221–31 The results of this study supports WHO change in definition of acute erythroid leukemia.CrossRef
26.
Lessard M, Struski S, Leymarie V, Flandrin G, Lafage-Pochitaloff M, Mozziconacci MJ, et al. Cytogenetic study of 75 erythroleukemias. Cancer Genet Cytogenet. 2005;163:113–22.CrossRef
27.
Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. Leukemia. 2013;27(9):1940–3.CrossRef
28.
Cervera N, Carbuccia N, Garnier S, Guille A, Adélaïde J, Murati A, et al. Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia. 2016;30:966–70.CrossRef
29.
Ko PS, Liu YC, Yeh CM, Gau JP, Yu YB, Hsiao LT, et al. The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification. PLoS One. 2017;12(2):e0172029.CrossRef
30.
• Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31(1):11–7 This study illustrates mutation profile in acute erythroleukemia.CrossRef
31.
•• Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017;129(18):2584–7 This study illustrates high rate of TP53 mutations in acute erythroleukemia.CrossRef
32.
•• Iacobucci I, Wen J, Meggendorfer M, Choi JK, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51:694–704 This large study compares genomic features of pediatric and adult acute erythroleukemia.CrossRef
33.
Panagopoulos I, Micci F, Thorsen J, Haugom L, Buechner J, Kerndrup G, et al. Fusion of ZMYND8 and RELA genes in acute erythroid leukemia. PLoS One. 2013;8(5):e63663.CrossRef
34.
Colita A, Belhabri A, Chelghoum Y, Charrin C, Fiere D, Thomas X. Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases. Ann Oncol. 2001;12(4):451–5.CrossRef
35.
Santos F, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, et al. Adult Acute Erythroleukemia: An Analysis of 108 patients treated at a single institution. Leukemia. 2009;23(12):227–80.CrossRef
36.
Greco R, Petrungaro A, Recchia AG, De Stefano L, Bossio S, Palummo A, et al. Treatment Acute Myeloid Leukemia Using Cytoreductive Chemotherapy Cytarabine (Ara-C) Followed Azacitidine (AZA) Maintenance: A Real Life Single Center Experience. Blood. 2016;128(22):5204.CrossRef
37.
Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. NEJM. 2016;375(21):2023–36.CrossRef
38.
•• Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, et al. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int J Mol Sci. 2017;18(4):837 This study supports use of HMAs in acute erythroleukemia.CrossRef
39.
Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, et al. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leuk Lymphoma. 2016;57(4):812–9.CrossRef
Metadaten
Titel
Erythroleukemia: an Update
verfasst von
Olga K. Weinberg
Daniel A. Arber
Publikationsdatum
01.06.2021
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 6/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01060-8

Weitere Artikel der Ausgabe 6/2021

Current Oncology Reports 6/2021 Zur Ausgabe

Orthopedic Oncology (JA Abraham, Section Editor)

Update on Osteosarcoma

Interventional Oncology (DC Madoff, Section Editor)

Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy

Correction

Correction to: Psychosocial Interventions for Pain Management in Advanced Cancer Patients: a Systematic Review and Meta-analysis

Interventional Oncology (DC Madoff, Section Editor)

Role of Machine Learning and Artificial Intelligence in Interventional Oncology

Interventional Oncology (DC Madoff, Section Editor)

Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy

Leukemia (A Aguayo, Section Editor)

Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise